EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Ginsenosides as Emerging Adjuvants for Immunotherapy in Gastrointestinal Cancers

Hamzeh J Al-Ameer, Omayma Salim Waleed, S Renuka Jyothi, Priya Priyadarshini Nayak, Siya Singla, Gurjant Singh, Annaev Umidjon iD, Azizjanov Khushnud Maksudovich, Manoj Kumar-Mishra

Journal of Gastroenterology and Hepatology · 2026-05 · 41 (5) · 1478-1493

DOI: 10.1111/jgh.70333 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 19.03.2026. Verfasst von Hamzeh J Al-Ameer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Hauptthemen laut MEDLINE: Ginsenosides, Gastrointestinal Neoplasms, Immunotherapy, Adjuvants, Immunologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 137 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrointestinal (GI) cancers remain a leading cause of cancer‐related death worldwide, and many patients with advanced disease still respond poorly to standard treatments such as surgery, chemotherapy, and radiotherapy. Immune checkpoint inhibitors have changed the management of several solid tumors, but their benefit in most GI malignancies is limited by low tumor mutational burden, microsatellite stability, and “cold” tumor immune microenvironments. This has created interest in safe adjuvant agents that can boost antitumor immunity and improve responses to immunotherapy. Ginseng, a traditional medicinal herb, contains ginsenosides and polysaccharides with documented antitumor and immunomodulatory activities. Experimental studies in liver, colorectal, gastric, and esophageal cancer models show that selected ginsenosides can promote apoptosis, modulate DNA damage responses, inhibit angiogenesis, reshape inflammatory signaling, and downregulate PD‐L1 or other resistance pathways. Ginseng‐derived nanoparticles and liposomal formulations further suggest a role in drug delivery and microenvironment remodeling. At the same time, clinical experience from traditional Chinese medicine indicates that ginseng‐based preparations may alleviate cancer‐related fatigue, support host immunity, and enhance tolerance to chemoradiotherapy. However, the pharmacological targets, optimal combinations, and predictive biomarkers for ginsenoside‐based adjuvant therapy remain poorly defined. Integration of systems pharmacology, single‐cell technologies, and modern clinical trial design will be essential to clarify the role of ginsenosides as partners in immunotherapy for GI cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GinsenosidesGastrointestinal NeoplasmsImmunotherapyAdjuvants, ImmunologicHumansPanaxAnimalsTumor MicroenvironmentApoptosisB7-H1 Antigen

Stichwörter der Autor:innen

gastrointestinal cancerginsenosidesimmune checkpoint inhibitorsimmunotherapytraditional Chinese medicine

Substanzen

GinsenosidesAdjuvants, ImmunologicB7-H1 Antigen

Autor:innen und Institutionen

  • Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
  • Department of Anesthesia Techniques, Health and Medical Techniques College, Alnoor University, Mosul, Iraq.
  • Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
  • Department of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan, Bhubaneswar, Odisha, India.
  • Centre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab, India.
  • Department of Physiotherapy, University Institute of Allied Health Sciences, Chandigarh University, Mohali, Punjab, India.

ORCID-Profile: Annaev Umidjon

Zitieren

APA

Al-Ameer, H. J., Waleed, O. S., Renuka Jyothi, S., Nayak, P. P., Singla, S., Singh, G., Umidjon, A., Maksudovich, A. K., & Kumar-Mishra, M. (2026). Ginsenosides as Emerging Adjuvants for Immunotherapy in Gastrointestinal Cancers. Journal of Gastroenterology and Hepatology, 41(5), 1478-1493. https://doi.org/10.1111/jgh.70333

Vancouver

Al-Ameer HJ, Waleed OS, Renuka Jyothi S, Nayak PP, Singla S, Singh G, et al. Ginsenosides as Emerging Adjuvants for Immunotherapy in Gastrointestinal Cancers. Journal of Gastroenterology and Hepatology. 2026;41(5):1478-1493. doi:10.1111/jgh.70333

BibTeX
@article{AlAmeer2026,
  author = {Al-Ameer, Hamzeh J and Waleed, Omayma Salim and Renuka Jyothi, S and Nayak, Priya Priyadarshini and Singla, Siya and Singh, Gurjant and Umidjon, Annaev and Maksudovich, Azizjanov Khushnud and Kumar-Mishra, Manoj},
  title = {Ginsenosides as Emerging Adjuvants for Immunotherapy in Gastrointestinal Cancers},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {5},
  pages = {1478--1493},
  doi = {10.1111/jgh.70333}
}
Kostenlos starten →